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ABSTRACT
Chronic inflammation has been recognized as a risk factor for the development
and maintenance of malignant disease. Cytokines such as interleukin-6 (IL-6),
oncostatin M (OSM), and interleukin-1 beta (IL-1β) promote the development of
both acute and chronic inflammation while promoting in vitro metrics of breast
cancer metastasis. However, anti-IL-6 and anti-IL-1β therapeutics have not yielded
significant results against solid tumors in clinical trials. Here we show that these three
cytokines are interrelated in expression. Using the Curtis TCGA™ dataset, we have
determined that there is a correlation between expression levels of OSM, IL-6, and IL1β and reduced breast cancer patient survival (r = 0.6, p = 2.2 x 10−23). Importantly,
we confirm that OSM induces at least a 4-fold increase in IL-6 production from
estrogen receptor-negative (ER−) breast cancer cells in a manner that is dependent
on STAT3 signaling. Furthermore, OSM induces STAT3 phosphorylation and IL-1β
promotes p65 phosphorylation to synergistically induce IL-6 secretion in ER− MDAMB-231 and to a lesser extent in ER+ MCF7 human breast cancer cells. Induction may
be reduced in the ER+ MCF7 cells due to a previously known suppressive interaction
between ER and STAT3. Interestingly, we show in MCF7 cells that ER’s interaction
with STAT3 is reduced by 50% through both OSM and IL-1β treatment, suggesting a
role for ER in mitigating STAT3-mediated inflammatory cascades. Here, we provide
a rationale for a breast cancer treatment regime that simultaneously suppresses
multiple targets, as these cytokines possess many overlapping functions that increase
metastasis and worsen patient survival.

INTRODUCTION

remains flat, and there has been little improvement in
the survival rate for stage IV metastatic breast cancer
over the past decade [2]. One of the contributing factors
to this phenomenon may be due to the increasing levels
of diabetes and obesity in the developed world which
contribute to the development of systemic inflammation
[3, 4]. In particular, breast cancer risk factors associated

Breast cancer-related morbidity and mortality
remains one of the top concerns for women worldwide
with 266,120 new cases of breast cancer predicted
for 2018 [1]. Despite new treatments and extensive
preventative screening initiatives, breast cancer incidence
www.oncotarget.com
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with obesity include metabolic abnormalities and
extensive adipose tissue accumulation in the midsection
[5]. Strong associations between obesity, cancer, and
inflammation have been demonstrated where there
has been enhanced breast cancer incidence rates and
worsening prognosis with increased obesity [4, 6–8].
Obesity results in elevation of inflammatory cytokines
such as interleukin-6 (IL-6), tumor necrosis factor-alpha,
(TNFα), and interleukin-1 beta (IL-1β), which have all
been linked to the development of breast cancer [9]. IL6, in particular, has been demonstrated to promote breast
tumor cell proliferation and metastatic capacity and to
decrease patient survival [10]. Although the importance
of IL-6 in cancer disease progression is well documented,
anti-IL-6 therapies such as siltuximab have not produced
clinically beneficial results for the treatment of solid
tumors such as prostate, colorectal, lung, and ovarian
cancers, although breast cancer was not yet tested
[11, 12]. This lack of effect suggests a potential
redundancy, where other pro-inflammatory mediators
may also be contributing to breast cancer metastasis and
reduced patient survival.
The IL-6 cytokine is a part of the gp130 family
of cytokines which include IL-6, oncostatin M
(OSM), leukemia inhibitory factor (LIF), IL-11, IL27, cardiotrophin-1(CT-1), ciliary neurotrophic factor
(CNTF), and cardiotrophin-like cytokine factor 1
(CLCF1) [13]. The receptors for each of these cytokines
have a shared gp130 subunit and signal a wide range
of inflammatory functions driving the pathogenesis of
malignancies [13–15]. OSM, in particular, has been shown
to induce tumor cell detachment, epithelial-mesenchymal
transition (EMT), invasive potential, induction of cancer
stem cells, immune evasion, osteolytic bone metastases,
and circulating tumor cell numbers [16–23]. OSM
functions through binding to the OSM receptor (OSMR),
a gp130/ OSMRβ complex, to induce downstream
signaling pathways such as signal transducer and activator
of transcription 3 (STAT3), mitogen-activated protein
kinase (MAPK), and AKT [24–26]. Interestingly, OSM
binds to acidic extracellular matrix (ECM) proteins at
high concentrations, stays active, and signals downstream
pathways in an in vitro model of the breast cancer
microenvironment [27]. This supports evidence that
breast tumors create their own acidic microenvironment
and suggest that OSM and other inflammatory factors
compound tumor-associated inflammation and lead to
increased tumor-cell aggressiveness [28, 29].
Few synergistic interactions between OSM and
other pro-inflammatory cytokines have been documented
in breast cancer [30, 31]. Synergistic interactions between
OSM, interleukin-1 (IL-1α), and IL-1β have been
demonstrated in the context of cartilage breakdown in
the joint, resulting in an amplified induction of matrix
metalloproteinases (MMPs), IL-8, as well as IL-6
expression [32–34]. Additionally, OSM and IL-1β have
www.oncotarget.com

been shown to synergistically induce vascular endothelial
growth factor (VEGF) expression in astroglioma cells
[35]. Both IL-1α and IL-1β activate the same IL-1
receptor, (a dimer of IL-1R1 and IL-1RAcP), while IL1α is a membrane-bound protein and IL-1β is a soluble
protein [36]. IL-1β promotes these effects through the
activation of NFκB p65 and MAPK-ERK pathways,
resulting in the release of cytokines [37–40]. Similar
to our published studies, which showed that OSM is
important for osteolytic breast cancer metastasis to bone
[19], IL-1β also stimulates the development of bone
metastases [41]. Unfortunately, anti-IL-1β therapies such
as anakinra (Kineret™) have not resulted in improved
clinical outcomes for patients with solid tumors, although
additional research and clinical trials are currently in
progress [42–45]. Furthermore canakinumab, another
anti- IL-1β therapeutic agent, had some effect against
lung cancer however it had no positive effect on all-cause
mortality due to increase in fatal infections [46].
In this study, we investigate the effect of OSM, IL-6,
and IL-1β on breast cancer patient survival as well as how
these cytokines are interrelated in terms of cell signaling.
Using the Curtis TCGA data set [47], we find that high
expression of OSM correlates with decreased breast cancer
patient survival, similar to previous studies with IL-6 [48].
Previous studies indicated that OSM induces IL-6 in some
cell types [49]. Interestingly, OSM induction of IL-6 only
occurs in the more aggressive ER− cell lines but not in the
ER+ cells lines tested in vitro. We also demonstrate that
co-treatment of ER− breast cancer cells with both OSM
and IL-1β leads to a synergistic increase in IL-6 secretion.
These results highlight the complex interactions between
OSM, IL-6, and IL-1β, which may render singular anticytokine treatments ineffective.

RESULTS
Tumor expression of OSM and IL-6 are
associated with decreased invasive breast cancer
survival and correlate with each other
Both OSM and IL-6 increase breast cancer
metastatic potential in vitro as well as promote metastasis
in vivo [10, 19, 24, 48, 50–54], suggesting that high
levels of these cytokines may negatively affect patient
survival. In particular, the literature suggests the use of
IL-6 as a prognostic marker for breast cancer metastasis
and survival [48]. To assess the relevance of tumor tissue
expression of OSM and IL-6 in the context of invasive
ductal carcinoma (IDC) patient survival, we used the
Curtis Breast dataset obtained from Oncomine™ [47].
The upper quartile was delineated as the top 25% of
patient expression levels (high expression), while the
lower quartile represents the bottom 25% expression
(low expression). High tumor tissue expression of OSM
(p < 0.001, Figure 1A) and IL-6 (p < 0.001, Figure 1B)
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each independently correlated with a significant decrease
in invasive breast cancer patient survival. In addition, high
co-expression of both OSM and IL-6 were significantly
correlated with decreased survival compared to low coexpression of both OSM and IL-6 (p = 0.0091, Figure 1C).
Further assessment revealed that the breast tumor
expression of OSM correlated with the expression of
IL-6, with a Spearman coefficient of 0.576 (p < 0.0001,
Figure 1D). Collectively, these results demonstrate that
the breast tumor expression levels of OSM and IL-6 are
correlated and that elevated breast cancer tissue levels of
these cytokines are associated with decreased survival.

muscle cells, osteoblasts, and astroglioma cells [49, 57, 58].
This prompted us to investigate whether OSM signals
mammary tumor cells to increase IL-6 expression in vivo.
We utilized an inducible-hOSM MDA-MB-231 orthotopic
mouse model of human breast cancer. MDA-MB-231Luc2 cells were stably transfected with a TET-inducible
hOSM expression vector (MDATO/OSM) cells and injected
into the 4th mammary fat pad of athymic nude mice. Once
the tumors were palpable (~3–5 mm in diameter), the
animals were given drinking water containing tetracycline
(+TET; 0.1 mg/mL, n = 3) with 2% sucrose or 2% sucrose
water alone (−TET, n = 3). MDATO/OSM tumor-bearing
animals +TET had a 32-fold higher expression of OSM
in their tumors compared to –TET tumors (Figure 3A)
and 10.8-fold higher IL-6 expression level (Figure 3B),
as measured by western blot analysis. Due to the poor
dynamic range of immunoblot imaging, only one mouse
in the +TET group appears to have high cytokine levels. A
follow up study with cytokines released into circulation,
on the other hand, show all three animals in the +TET
treated group have elevated OSM and IL-6.
Blood was collected from these mice and hOSM and
hIL-6 serum levels were assessed by ELISA. TET-treated
mice had higher levels of hOSM (9.8-fold, Figure 3C
Left) and IL-6 (96-fold, Figure 3C Right) in their serum,
and the concentrations correlated with each other with
an r2 coefficient of 0.9058 (p = 0.0034, Supplementary
Figure 1). These findings definitively demonstrate that
increased hOSM results in increased hIL-6 expression and
secretion in the mammary tumors and serum of MDATO/OSM
mice, which concurs with both our breast cancer patient
serum data and the Curtis breast cancer tumor expression
data from Oncomine.

High serum levels of OSM in breast cancer
patients correlate with high IL-6 levels
Previous studies suggest that elevated expression
of growth factors and cytokines in the tumor
microenvironment (TME) can result in these proteins
leaking into the circulation and becoming detectable
in patient serum [55, 56]. To determine whether serum
concentrations of OSM and IL-6 also correlate with
disease progression and with each other, as seen with
breast tumor expression in Figure 1, we assessed serum
samples collected from a total of 186 breast cancer
patients and healthy individuals by ELISA. First, breast
cancer patient serum had significantly higher levels of
OSM and IL-6 compared to serum from individuals
without malignancies (Figure 2A, 2B). Patients with
non-metastatic breast cancer had 3.8-fold higher level
of serum OSM compared to normal healthy volunteers,
whereas patients with metastatic breast cancer had 4.9fold higher levels of serum OSM (Figure 2A). Similarly,
serum IL-6 levels were 10.5-fold and 15.6-fold higher
in non-metastatic and metastatic breast cancer patients,
respectively, compared to normal healthy volunteers
(Figure 2B). Secondly, serum samples with detectable
OSM (> 0 pg/mL) also had significantly higher levels of
IL-6, while samples with no OSM contained little to no
IL-6 (Figure 2C), suggesting that OSM may cause IL-6
production. Finally, a correlation analysis revealed that
serum OSM and IL-6 concentrations were statistically
correlated, with a Spearman coefficient of 0.3774
(p < 0.0001, Figure 2D). Together, these results clearly
demonstrate that breast cancer progression is associated
with increased serum levels of both OSM and IL-6 and
that the serum concentrations of these two cytokines
correlate with each other, similar to the results with tumor
expression levels of OSM and IL-6.

OSM induces human IL-6 secretion in the
absence of ER from various cancer cells in vitro
Our results indicate that there is a strong correlation
between OSM and IL-6 expression and secretion levels
in breast cancer. To assess whether OSM induces IL-6
cytokine production in breast cancer cells, various cell
lines including two human ER+ cell lines, T47D and
MCF7, and three ER− cell lines MDA-MB-468, MDAMB-231, and 4T1.2 mouse mammary cancer cells
were utilized. The cells were treated with human or
mouse rOSM for 48 hours, and secreted IL-6 levels in
the conditioned media (CM) were assessed by ELISA.
Interestingly, OSM did not induce IL-6 secretion in the
ER+ MCF7 or T47D cells but did induce IL-6 secretion
in the ER− cells (Figure 4A). OSM promoted IL-6
secretion approximately 5-fold in MDA-MB-468 cells,
~4-fold in MDA-MB-231 cells, and ~4-fold in 4T1.2
mouse mammary carcinoma cells (Figure 4A). Nonbreast cancer, estrogen receptor-negative cell lines were
also tested for OSM-induced IL-6 secretion, including
PC3 and DU145 human prostate cancer cells, as well as

OSM promotes IL-6 secretion in mammary
tumors
Our studies with breast cancer patients showed that
high serum levels of OSM and IL-6 are correlated, and
OSM has been shown to induce IL-6 expression in smooth
www.oncotarget.com
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HeLa human cervical carcinoma cells. ER− and androgen
receptor-negative (AR-) PC3 cells expressed high levels
of IL-6 with or without OSM, while OSM-induced an
approximately 6.5-fold increase in IL-6 secretion from
ER− AR- DU145 cells, (Figure 4B) and a 30.5-fold in ER−
HeLa cells (Figure 4B). Importantly, IL-6 had no effect on
OSM secretion in MDA-MB-231, T47D, or MCF7 breast

cancer cells (Supplementary Figure 2), suggesting no
reciprocal induction of cytokine secretion. These results
show that OSM increased IL-6 expression in all aggressive
tumor cell lines tested and that this induction may be
associated with ER status.
To assess whether the presence of ER suppresses
OSM induction of IL-6, we created ER− cells that stably

Figure 1: OSM and IL-6 are associated with decreased invasive breast cancer survival. (A) Kaplan–Meier curves of

invasive breast cancer patient samples with high OSM expression levels show significant reduction in survival compared to curves of
patients with low OSM expression levels. Log-rank test (p < 0.0001) (B) This trend is repeated with IL-6. Survival curves of breast
cancer patients with high IL-6 expression have reduction in survival compared to patients with low IL-6 expression level Log-rank test
(p < 0.0001). (C) Survival curves of breast cancer patients with high co-expression of OSM and IL-6 also demonstrate a reduction in
survival compared to patients with low co-expression of both OSM and IL-6 Log-rank test (p = 0.0091). (D) Two-way correlation analysis
depicts a statistically significant correlation between OSM and IL-6 expression levels in breast cancer patients with a Spearman coefficient
of 0.576. (p < 0.0001).
www.oncotarget.com
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express estrogen receptor. ER− MDA-MB-231 cells
were stably transfected with an ERα expression vector
(pEGFP-C1). Two independent colonies, MDAER+/C7
and MDAER+/H6, were shown to express ER by western
blot analysis (Figure 4C). To assess OSM-induced IL-6
secretion in the new ER+ cells, parental MDA-MB-231,
MDAER+/C7, and MDAER+/H6 cells were treated with rhOSM
(25 ng/mL) for 48 hours. CM was collected and IL-6
concentrations were analyzed by ELISA. MDAER+/C7
cells exhibited a 7.8-fold decrease, and MDAER+/H6 cells
demonstrated a 12.1-fold decrease in the levels of IL-6
produced in response to OSM, as compared to the parental

MDA-MB-231 cells (Figure 4D). These results indicate
that the ER+ MDA-MB-231 cells have limited OSMinduced IL-6 expression and suggest that ER may play a
negative regulatory role in the OSM signaling that leads
to IL-6 expression.

OSM works synergistically with IL-1β to
increase IL-6 secretion
The inflammatory proteins OSM and IL-1β have
been demonstrated to have a synergistic effect on IL-6
production in the context of bone and muscle cells

Figure 2: OSM breast cancer patient serum levels correlate with IL-6 levels. Serum from breast cancer patients were procured

from various sources, and OSM levels (A) and IL-6 levels (B) were measured by ELISA. When OSM and IL-6 were assessed between
normal patients versus patients with non-metastatic or metastatic breast cancer, there was a significant increase in serum OSM and IL-6
levels in both patients with non-metastatic or metastatic breast cancer versus normal patients. (C) Patient sera with undetectable OSM levels
also have low IL-6 levels (8.5 pg/ml), while patient sera with detectable levels of OSM have high levels of IL-6 (89 pg/ml). (D) The serum
cytokines concentration data was then assessed for correlation and suggests that higher levels of serum OSM correlates with higher levels
of serum IL-6 (Spearman Correlation coefficient = 0.923 (95% CI 0.825, 1.0) P < 0.0001). Data expressed as mean ± SEM. and assessed
by one-way ANOVA with Tukey’s post-test *p < 0.05, **p < 0.01, ***p < 0.001.
www.oncotarget.com
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[49, 59]. Knowing that inflammation plays a major role in
breast cancer pathogenesis, we sought to elucidate whether
OSM and IL-1β work together to promote IL-6 secretion
in breast cancer. To reduce the probability of saturating
the cell’s capacity to produce IL-6 and to better assess a
possible synergistic interaction between OSM and IL-1β
in breast cancer cells, we decreased the amount of OSM
used in the experiments from 25 ng/mL to 10 ng/mL.
Treating ER− MDA-MB-231 cells with a combination
of OSM and IL-1β (10 ng/mL) for 72 hours resulted in a
44.8-fold increase in IL-6 secretion by ELISA, while OSM

alone leads to a 6.4-fold increase and IL-1β alone lead to
a 17.3-fold increase compared to untreated cells (Figure
5A). This result suggested that OSM and IL-1β induced
IL-6 secretion in a synergistic manner in ER− cells. As
demonstrated in Figure 4A, no induction of IL-6 secretion
by OSM was seen in either ER+ T47D or MCF7 cells.
After adjusting the scale for IL-6 secretion levels, a slight
increase in IL-6 secretion by IL-1β was seen in ER+ MCF7
cells, as compared to untreated controls (Figure 5B).
MCF7 cells also exhibited a synergistic 24.8-fold increase
in IL-6 secretion by treatment with both OSM and IL-1β

Figure 3: OSM induces IL-6 in an animal model of human breast cancer. (A) MDATO/OSM cells were injected orthotopically

in vivo in athymic nude mice. After the tumors became palpable, the animals were given tetracycline, and after one week, the animals
were sacrificed and tumors harvested. Western blot analysis of the tumors indicates that OSM levels increase in response to tetracycline
administration (top). Densitometry of western blots indicate a 32-fold increase in tumor OSM in animals given tetracycline compared to
animals given control water (bottom). (B) IL-6 levels in the tumor, as assessed by western blot, also show similarly elevated levels in the
tetracycline-treated animals (10.8-fold). (C) Sera collected from the animals were assessed for hOSM and hIL-6 levels by ELISA. Animals
given tetracycline have a 9.8-fold increase in mean serum hOSM levels and an 96-fold increase in mean serum hIL-6 levels. Data expressed
as mean ± SEM, and significance assessed by two-tailed student’s t-test. *p < 0.05.
www.oncotarget.com
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compared to IL-1β alone (Figure 5B). Although the level
of IL-6 production was much lower in the ER+ MCF7
cells compared to the ER− MDA-MB-231 cells, there was
a clear indication of a synergistic relationship between
OSM and IL-1β in this cell line as well. T47D cells, on the
other hand, were unable to produce any IL-6 in response
to OSM or IL-1β, even though the cytokine’s activity was
confirmed by an increased EMT-like morphology and the
formation of invadopodia-like structures (Supplementary
Figure 3). These results suggest that OSM and IL-1β may
be activating separate pathways to synergistically increase
IL-6 secretion. Importantly, these findings also indicate

that even when ER+ breast cancer cells, such as T47D
cells, are unable to produce IL-6 in response to OSM
or IL-1β, they can still undergo invasive characteristics
independently of IL-6 [21].

Early OSM and IL-1β activate STAT3 and p65
signaling pathways to promote IL-6 production
The synergistic upregulation of IL-6 secretion in
response to OSM and IL-1β suggests that these cytokines
may be using separate pathways to promote IL-6 in
breast cancer cells. It is well known that IL-1β utilizes

Figure 4: OSM induces IL-6 secretion in an ER-dependent manner. (A) IL-6 secretion levels were measured by ELISA on

CM collected from various OSM-treated cells. ER− MDA-MB-231, MDA-MB-468, and 4T1.2 cells display high (over 4-fold) levels of
OSM-induced IL-6 secretion, while ER+ MCF7, and T47D cells do not. (B) OSM also induces IL-6 secretion in PC3 and DU145 (prostate)
and HeLa (ovarian) ER− non-breast cancer cell types. (C) MDA-MB-231 cells were transfected with an ERα expression vector, and the
presence of ERα in transfected colonies was determined by western blot. The two ER expressing cell lines are designated as MDAER+/C7
and MDA ER+/H6. (D) MDAER+/C7 cells secrete 9-fold less IL-6 and MDAER+/H6 cells secrete 12-fold less IL-6 in response to OSM compared
to the parental MDA-MB-231 cells. Data expressed as mean ± SEM and significance assessed by one-way ANOVA with Tukey’s post-test.
*
p < 0.05, **p < 0.01, ***p < 0.001.
www.oncotarget.com
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for only 20 minutes (Figure 5C), and activated signaling
molecules were assessed by western blot analysis. In
all breast cancer cell lines tested, OSM specifically
induced STAT3 phosphorylation (pSTAT3), while IL-

the NFκB pathway to induce IL-6 production [60]. To
investigate potential signaling differences between OSM
and IL-1β in MDA-MB-231, T47D, and MCF7 cells,
the cells were treated with both cytokines (10 ng/mL)

Figure 5: OSM and IL-1β activate separate signaling pathways and synergistically induce IL-6 secretion. (A) IL-1β alone

promotes IL-6 production in MDA-MB-231 and MCF7 cells, while a combination of OSM and IL-1β causes a synergistic response in IL-6
secretion. T47D cells do not produce IL-6 in any of these conditions. (B) Reduced IL-6 scale to allow visualization of MCF7 cell-IL-6
induction. (C) A 20-minute cytokine treatment with OSM induces the phosphorylation of STAT3 but not p65, while ERK is moderately
phosphorylated. MCF7 cells have a weak pSTAT3 induction in response to OSM. A 20-minute cytokine treatment with IL-1β on the other
hand induces the phosphorylation of p65 but not STAT3. (D) STAT3 siRNA suppressed OSM induction of IL-6 production as assessed by
ELISA in MDA-MB-231 cells. Data expressed as mean ± SEM, and significance assessed by one-way ANOVA with Tukey’s post-test.
*
p < 0.05. (E) MCF7 cells were treated with OSM and/or IL-1β for 48 hours, and the cell lysates were run through an immunoprecipitation
with an ER pulldown. The eluate was then immunoblotted with the input for STAT3. Lysates collected from MCF7 cells treated with OSM
or with both cytokines have significantly reduced ER-STAT3 interaction. Data expressed as mean ± SEM, and significance assessed by
one-way ANOVA with Tukey’s post-test. *p < 0.05.
www.oncotarget.com
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1β induced phosphorylation of p65 (pp65), a subunit of
the transcription factor NFκB. In contrast, OSM did not
induce pp65 and IL-1β did not induce pSTAT3 (Figure
5C). Additionally, long-term treatment by OSM does not
affect total STAT 3 levels [61]. IL-6 has also been known
to moderately activate STAT3, [61] but it is unlikely that
enough IL-6 accumulated by OSM treatment within 20
minutes to have a significant impact on IL-6 mediated
STAT3 phosphorylation.
Further investigation using siRNA (20 nM) against
STAT3 showed that siSTAT3 completely abrogated OSMinduced IL-6 secretion in MDA-MB-231 cells as detected
by ELISA (Figure 5D), thereby implicating STAT3 as the
primary signaling pathway responsible for OSM induction
of IL-6 secretion. On the other hand, STAT3 siRNA had
no effect on IL-1β-induced IL-6 levels (Supplementary
Figure 4). These findings demonstrate a clear role for
STAT3 signaling in ER− breast tumor cell OSM-induced
IL-6 and confirm that STAT3 is not able to induce IL-6
expression in ER+ T47D or MCF7 cells despite the
apparent phosphorylation of STAT3 by OSM.

synergistic manner with OSM signaling through STAT3
and IL-1β operating through p65.

Invasive breast cancer patient stroma expresses
high levels of OSM and IL-1β
We have demonstrated that OSM and IL-1β act
synergistically in the production of IL-6 by breast cancer
cells and in the potential exacerbation of inflammatory
conditions. It is known that cytokines such as OSM in
the stroma of the breast cancer microenvironment play
a major role in the progression of metastatic disease
[64], and is possible that IL-1β may also have this type
of prometastatic effect. To assess the clinical relevance
of this synergistic interaction between OSM and IL-1β,
we analyzed the stromal expression patterns of OSM
and IL-1β in both normal and invasive breast cancer
patient data using the Finak Breast Stromal dataset [65]
obtained from Oncomine™. Stromal OSM expression
was 5.9-fold higher in invasive breast cancer compared
to normal breast samples (Figure 6A), and stromal IL-1β
was 5.4-fold higher in invasive breast cancer compared
to normal samples (Figure 6B). A small but significant
increase in stromal OSM (Supplementary Figure 6A)
and IL-1β expression (Supplementary Figure 6B) in ER−
samples compared to ER+ samples was also seen. Using
the Curtis dataset, a significant increase in tumor OSM
expression (Supplementary Figure 6C), as well as tumor
IL-1β expression (Supplementary Figure 6D), was seen
in ER− samples compared to ER+ samples. These data
suggest that in breast cancer patients both paracrine and
autocrine production of OSM and IL-1β may work in an
ER-dependent manner to affect patient survival.

ER interaction with STAT3 is suppressed by
OSM and IL-1β in MCF7 cells
MDA-MB-231 cells lack ER and subsequently have
high levels of IL-6 secretion in response to OSM and IL1β, while ER+ cells either have no secretion or limited
secretion in response to these cytokines. In other studies,
ER has been shown to interact directly with various
signaling molecules such as p65 and to suppress its
downstream signaling despite p65’s apparent activation by
protein phosphorylation [62]. To assess whether ER may
be binding to intracellular signaling pathway proteins, an
immunoprecipitation with ER pull-down was performed
on ER+ MCF7 and T47D cell lysates treated with OSM
and/or IL-1β for 48 hours. While no interaction between
ER and p65, AKT, or ERK was observed (data not shown),
a 50% reduction in interaction between ER and STAT3 in
response to OSM or IL-1β in MCF7 cells was seen using
a STAT3 immunoblot of ER-immunoprecipitation eluates
(Figure 5E). With T47D cells, no interaction between
ER and any of the signaling proteins was detected (data
not shown). This suggests that the interaction of ER
with STAT3 may suppress OSM induction of IL-6 in
MCF7 cells and that in the ER+ T47D cells, a different
mechanism may be operant. Alternatively, there may
be cross talk between p65 and STAT3 for downstream
signaling [63], and suppression of ER-STAT3 interaction
by OSM and IL-1β may be needed for this crosstalk to
occur. Our data also show that OSM adversely affects
the survival of ER+ patients to a greater extent than the
survival of ER− patients (Supplementary Figure 5). This
suggests that further ER-specific interactions with OSM
signaling may exist, thus requiring future investigation.
Collectively, OSM and IL-1β appear to induce IL-6 in a
www.oncotarget.com

High tumor OSM and IL-1β levels are associated
with increased lymph node metastases and
decreased survival
The correlation between tumor OSM and IL1β expression and metastatic capacity was assessed in
the Curtis patient dataset. A 2.1-fold increase in lymph
node metastasis seen with high OSM versus low OSM
expression for invasive breast cancer (Figure 6C Left).
Similarly, lymph node metastasis was higher in IDC
patients with high IL-1β expression (Figure 6C Center).
Furthermore, when both OSM and IL-1β co-expression
was high, there was a 2.3-fold increase in lymph node
metastases compared to the low OSM and IL-1β coexpression group (Figure 6C Right). While, IL-1β alone
does not appear to affect breast cancer patient survival
(Supplementary Figure 7), high co-expression of OSM
and IL-1β also led to decreased patient survival (Figure
6D). In addition, OSM expression levels correlated with
IL-1β expression level (Supplementary Figure 8A) and
IL-1β expression levels correlated with IL-6 expression
level (Supplementary Figure 8B). To determine whether
2076
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Figure 6: OSM and IL-1β expression is higher in invasive breast cancer compared to normal tissue and correlates with
higher lymph node metastasis, decreased survival, and IL-6 levels. (A) Using the FINAK dataset obtained from Oncomine™ we

assessed stromal tissue expression of OSM and IL-1β. Stromal tissue expression of OSM is 5.9-fold higher in invasive breast cancer patients
compared to normal patients. (B) Similarly, expression of IL-1β is 5.4-fold higher in the stromal tissue of invasive breast cancer patients
compared to normal patients. (C) Using the Curtis dataset obtained from Oncomine™, we correlated OSM and IL-1β tissue expression
levels to the number of lymph node metastases. Patients with high OSM (Left), high IL-1β (Center), and high co-expression of both OSM
and IL-1β (Right) have significantly higher number of lymph node metastatic nodules compared to the respective low expression group.
(D) High co-expression of both OSM and IL-1β leads to a decreased overall patient survival. Log-rank test (p = 0.0401). (E) Expression
of OSM, IL-1β, and IL-6 were analyzed in a three-way correlation analysis with OSM on the x-axis, IL-6 on the y-axis, and IL-1β on the
z-axis. There is significant correlation with a coefficient of 0.6001, with a p-value of 2.2 × 10−23. Bar and scatter plot data expressed as mean
± SEM, and significance assessed by two-tailed student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001.
www.oncotarget.com
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all three cytokines were correlated with each other, OSM,
IL-6, and IL-1β expression levels were assessed using a
least squares multiple correlation analysis (Figure 6E).
The three-way correlation coefficient of OSM, IL-6, and
IL-1β was 0.6001, with a p-value of 2.2 × 10−23, indicating
a strong correlation between the three cytokines in these
IDC tumors. Collectively, these results suggest that OSM,
IL-6, and IL-1β are interrelated in breast cancer patient
metastasis and survival. Furthermore, these results
demonstrate that not only does high expression of each
one of these cytokines increase metastasis and decrease
survival in breast cancer patients, but OSM and IL-1β also
induce the expression of IL-6. This may provide at least in
part, an explanation as to why clinical trials using single
anti-cytokine therapies thus far have failed for metastatic
breast cancer patients.

compared to normal healthy volunteers. This was partially
recapitulated in an in vivo mouse model of breast cancer
where mice bearing MDA-MB-231 tumors with a TETinducible expression of OSM. Not only were the OSM
serum levels higher in animals with induced expression of
OSM, IL-6 levels were also elevated in the serum. While
serum IL-6 levels have previously been demonstrated to
be correlated with breast cancer development and reduced
survival [71], this is the first study investigating OSM.
Our data demonstrate that OSM and IL-6 expression levels
correlate in the breast tumor microenvironment, breast
cancer patient serum, and in in vivo mouse studies.
Interestingly, our in vitro results demonstrated
that OSM induced IL-6 in breast cancer cells in an ER−
dependent manner, while OSM did not promote secretion
of IL-6 in ER+ cell lines. We showed that suppression
of the STAT3 pathway by siRNA reduced OSM-induced
IL-6 production to untreated control levels in ER− MDAMB-231 cells. Constitutive expression of ER in MDAMB-231 cells also resulted in suppressed OSM-induced
IL-6. Previous studies and our data indicate that canonical
expression of IL-6 is dependent on the NFκB pathway
and that ER suppresses this signaling through inhibition
of p65 [62, 72]. However, our immunoprecipitation results
suggest that ER may interact with STAT3 to suppress
OSM-induced-IL-6 secretion. Taken together, this
suggests that OSM induces IL-6 secretion in the MDAMB-231 cells through the STAT3 pathway and that ER
appears to inhibit downstream STAT3 signaling (Figure 7).
Other cytokines such as IL-1β have been known to
synergistically interact with OSM in the context of joint
damage and synovial fibroblast-mediated inflammation
[32, 59]; however, the exact nature of this interaction
has not been studied in breast cancer. Our in vitro results
indicated that OSM works with IL-1β to synergistically
increase IL-6 production in MDA-MB-231 cells. On the
other hand, ER+ MCF7 cells produced IL-6 in response
to IL-1β and OSM co-treatment but not OSM alone,
and ER+ T47D cells did not produce IL-6 under any
conditions tested. This suggests that despite both of these
cell lines being luminal A breast cancer cell subtype (ER+/
PR+/HER2-), there exist significant differences in their
intracellular signaling mechanisms. We also showed that
induction of IL-6 by IL-1β alone or by both OSM and
IL-1β was not affected by STAT3 siRNA in either MDAMB-231 or MCF7 cells. This suggests that OSM and IL1β work synergistically to increase IL-6 production by
activating two separate pathways, STAT3 and NFκB in
ER− MDA-MB-231 cells.
Our immunoprecipitation result in MCF7 cells
also suggested that treatment of the cells with OSM, IL1β, or with both cytokines reduced the association of ER
with STAT3. Initially, this seems to be an unusual result
as IL-1β does not utilize the STAT3 pathway to induce
downstream signaling. However, there appears to be some
measure of crosstalk reported in the literature between the

DISCUSSION
Previous therapeutic interventions against
inflammatory cytokines such as IL-6 and IL-1β have failed
in clinical trials despite their well-known role in tumor
and metastasis promotion [10, 11, 13]. Nevertheless, with
the growing acceptance that chronic tumor inflammation
leads to angiogenesis, immunosuppression, proliferation,
and metastasis [29], there has been a renewed interest in
mitigating inflammation in the tumor microenvironment.
In fact, we have recently demonstrated that high tumor
expression of OSM or IL-6 along with high VEGF
expression is associated with poor survival in HER2breast cancer patients [61]. Individually, inflammatory
cytokines such as OSM, IL-6, and IL-1β have been shown
to promote effects associated with metastatic cancer
[10, 27, 36, 66]. Our results here suggest that inflammation
in the tumor microenvironment may be instigated by
multiple cytokines and that the highly-studied IL-6 may
only be a limited part of the whole picture. Here we show
for the first time the interplay between the three cytokines
in breast cancer.
In this study, we reveal a novel finding which
demonstrates that high expression of OSM and IL-6 in
breast cancer tumors are correlated with reduced breast
cancer patient survival. Other studies have linked the OSM
receptor to poor prognosis and reduced patient survival is
in cervical carcinoma [18, 67] but not to the soluble OSM
cytokine. Previous studies have shown that high levels
of inflammatory cytokines such as IL-6 increase the risk
of breast cancer development and progression [68] and
that IL-6 also promotes cancer cell aggressiveness and
metastasis to distant organs such as to the bone [10]. While
there has been a suggestion that IL-1β may also play a role
in breast cancer progression [69, 70], a specific correlation
to patient survival has not been previously made.
Our follow up studies using human patient
serum demonstrated that high levels of OSM and IL-6
were detected in the serum of breast cancer patients
www.oncotarget.com
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STAT3 pathway and the p65 pathway, where in some cases
the function of the pathway may be interdependent on
one another [73]. While the exact nature of the crosstalk
mechanism is not well known, it appears that NFκB and
STAT3 signaling proteins must be activated and directly
bind to each other during signaling [73, 74] (Figure 7).
However, if this is the case, STAT3 siRNA should have
inhibited IL-1β-mediated IL-6 secretion in MDA-MB-231
and MCF7 cells.
A possible alternative explanation for the lack of any
inhibitory activity of STAT3 siRNA on IL-1β-induced IL-6
secretion is that that ER forms an inhibitory complex with
STAT3 to suppress IL-6 expression [75]. This is similar to
the ER/p65 complex which is known to have a regulatory
role in gene expression [75]. This would make suppression
of total STAT3 ineffective for reduction of IL-6
expression, as doing so would also render the ER-STAT3
inhibitory complex less effective at regulating IL-6 gene
expression. Another possibility is that STAT3 interacts
with other STATs in conjunction with ER, such as STAT5,
which has some opposing effects against STAT3 signaling
in breast cancer cells thus reducing the overall cancer cell
aggressiveness [76]. Similarly, STAT1 also appears to have
some inhibitory effects against STAT3 signaling [77]. As

we have not been able to elucidate the exact mechanism of
STAT3/ER interaction and the crosstalk with NFκB, these
results necessitate an investigation into pathways that are
not necessarily canonically known to be activated by the
specific cytokine. Therefore, further investigation into
the mechanistic nature of how these signaling pathways
interact with each other in the context of breast cancer is
needed.
Utilizing the Curtis breast cancer data set, we
demonstrated that expression of OSM and IL-1β levels
in the breast microenvironment are elevated in breast
cancer and that high expression of these cytokines leads
to increased metastatic potential and reduced breast cancer
patient survival. Previous studies showed similar results
where the IL-6 and IL-8 cytokines were associated with
increased lymph node metastases and reduced survival
[78]. Furthermore, OSM, IL-6, and IL-1β expression
levels in breast cancer tissue are all strongly correlated
with each other. Other studies have also reported the
presence of cytokine co-expression such as tumor necrosis
factor alpha (TNFα) expression with IL-6 to have a
prognostic significance in breast cancer [79].
Collectively, our study demonstrates that OSM,
IL-6, and IL-1β expression levels are correlated with

Figure 7: OSM and IL-1β promote IL-6 expression in a breast cancer cell-subtype specific manner. OSM signals through

the STAT3 pathway and leads to IL-6 induction in ER− cells, while IL-1β induces IL-6 through the p65 pathway. In ER+ cells, ER may be
interacting with STAT3 to suppress IL-6 production. There may also be some crosstalk-like interaction between STAT3 and p65, however
the exact nature of this interaction is not known [73, 74].
www.oncotarget.com
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each other and that cytokine signaling differs in an ER
subtype-specific manner. OSM and IL-6 have previously
been implicated in the production of proangiogenic factors
such as VEGF to promote breast cancer progression
and reduced patient survival [61]. Together, our results
highlight the possible implications of multi-cytokine
effects in the tumor microenvironment and have important
clinical implications in that singular anti-cytokine
therapies may not be sufficient for the successful treatment
of metastatic breast cancer. In conclusion, this study
substantiates the rationale for a therapeutic design that
simultaneously targets multiple cytokines, such as OSM,
IL-6, and IL-1β, as these cytokines are strongly correlated
with each other in breast cancer.

Maryland). Patients and healthy control subjects with
evidence of autoimmune disease or recent infection with
bacterial or viral disease were excluded from the study.
However, the serum collection was not controlled for
either body mass index (BMI) or the presence of metabolic
diseases (in the absence of any evidence for autoinflammatory states), as the effect of these factors appear
to be nonspecific on serum cytokine levels. The serum
was diluted 1:3 in PBS and used in the DuoSet ELISA
for IL-6 (DY206, R&D system) or for OSM (DY295,
R&D systems) on Immulon HBX4 ELISA plates (3855,
ThermoFisher) in accordance with the manufacturer’s
instructions. Data was analyzed using GraphPad Prism
5.0 to determine correlations between OSM-IL-6 serum
concentrations.
Cells were incubated with OSM or IL-1β treatments
(10 ng/mL) ranging from 48–72 hours and the resultant
cytokine levels were assessed. To measure human IL-6 and
OSM in conditioned media, the same R&D ELISA kits
were utilized according to the manufacturer’s instructions.
Conditioned media from MDA-MB-231 cells were diluted
1:10 to 1:20 in order to accurately detect the amount of
IL-6 within the range of the standard. Conditioned media
was collected from 24-well plates containing 1 × 105 cells
at the time of cell plating.

MATERIALS AND METHODS
Oncomine analysis
The Curtis human breast cancer mRNA microarray
dataset [47] and the Finak breast cancer stromal gene
expression mRNA dataset [65] were obtained from
Oncomine™ (Compendia Bioscience, Ann Arbor, MI).
For survival analysis, the Curtis dataset was filtered
for “Invasive Ductal Carcinoma” and valid “Alive” or
“Dead of Disease” status. Patients with the status “Not
Dead of Disease” were removed from the study. From
the filtered dataset, upper (>75th percentile), and lower
(<25th percentile) quartiles of gene expression for OSM,
IL-6, and IL-1β were selected for comparison. For multigene co-expression analysis, we calculated for patients
high in both OSM and IL-6, or OSM and IL-1β. Survival
statistical analysis was performed using a log-rank test in
GraphPad Prism 5 software.
To analyze gene correlations, the Curtis dataset was
subjected to a correlation analysis using GraphPad Prism
5 software and the RealStatistics package on Microsoft
Excel. To assess gene expression levels of OSM and IL1β in stromal tissue, patients in the Finak dataset were
separated into normal and breast cancer categories, as
well as into ER+ and ER− breast cancer categories.
Additionally, the Curtis dataset was also separated into
ER+ and ER− breast cancer categories to assess gene
expression levels in the tumor cells. Statistical analysis
was performed using the 2-tailed student’s T-test in
GraphPad Prism 5 software.

Cell lines
MDA-MB-231, T47D, MCF7, and MDA-MB-468
human breast cancer cells, PC3 and DU145 human
prostate cancer cells, and HeLa human cervical cancer
cells were obtained from the American Type Culture
Collection (Rockville, MD, USA). All human cell lines
were maintained in RPMI 1640 media supplemented
with 10% fetal bovine serum and to 100 units/mL of
streptomycin and penicillin (Hyclone, Logan, UT, USA).
4T1.2 mouse mammary carcinoma cells were maintained
in MEM-alpha media supplemented with 10% fetal bovine
serum and to 100 units/mL of streptomycin and penicillin.
All cells and experimental incubations were maintained at
37° C, 5% carbon dioxide, and 100% humidity in a waterjacketed cell culture incubator.

Stable and transient transfections
To generate stably transduced MDA-MB-231 Luc2
D3H2LN cells (Caliper Life Sciences) with inducible
expression of OSM, the OSM cDNA (862 bp) (A generous
gift from Dr. Atsushi Miyajima, The University of Tokyo)
was cloned into the pLenti 6.3/TO/V5-DEST vector
(A11144 ThermoFisher). The vector+hOSM was then cotransduced with pLenti3.3/TR (A11144, ThermoFisher)
into MDA-MB-231 Luc2 D3H2LN cells using the
ViraPower™ II Lentiviral Gateway® Expression System
(K367-20, Life technologies) using the manufacturer’s
instructions. Stably transduced cells were injected into

Enzyme linked immunosorbent assay
Serum was collected from breast cancer patients
of various stages at St. Luke’s Mountain States Tumor
Institute (MSTI) and handled in accordance with the
St. Luke’s Medical Center (12-0298) and Boise State
University (006-MED15-006) Institutional Review Boards
(IRB). Additional serum was purchased from Proteogenix
(Schiltigheim, France) and Bioreclamations (Baltimore,
www.oncotarget.com
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mice and resultant tumors and animal sera tested for TET
induction by western blot and ELISA. The stable TET
inducible OSM expressing MDA-MB-231 Luc2 D3H2LN
clone has been designated as MDATO/OSM.
To generate stable expression of estrogen receptor
alpha (ERα) in ER− MDA-MB-231 cells, an ERα
expressing plasmid (Cat# 28230, AddGene) was stably
transfected into MDA-MB-231 cells using Lipofectamine
LTX (Cat# 15338100, Life Technologies). For control
cells, an empty pEGFP-C1 (Cat#6084-1, Clontech)
vector was stably transfected into these cells. Cells were
transfected at 80% confluency in 96-well plates containing
RPMI 1640+10% FBS with 6 µg DNA per well and a
Lipofectamine:DNA ratio of 1.35:1. Transfected cells
were selected for using G418 at a concentration of 500
μg/mL. Surviving colonies were expanded under antibiotic
pressure and their expression of ERα was verified by
western blot analysis.
To transiently suppress STAT3, a siRNA pool
targeting STAT3 was purchased from Dharmacon (Cat
#L-003544-00-0005). 100,000 cells per well were
seeded in a 24-well plate, and the siRNA was transfected
in accordance to the Fast-Forward protocol as per the
technical manual included with the Hyperfect siRNA
transfection reagent (Cat# 301705, Qiagen). STAT3
siRNA was used at 25 nM and the cells were transfected
for 72 hours before being treated with OSM or IL-1β.
Knockdown of STAT3 was assessed by western blot.

(25 ng/mL) was used to treat all human cell lines, and
recombinant mouse OSM (rmOSM; 25 ng/mL) was
used for the 4T1.2. Cells were treated for 30 minutes
or 72 hours. Conditioned media was collected from the
cells treated for 72 hours, and cell lysates were collected
from both time points using 1× RIPA buffer containing a
protease inhibitor cocktail (Sigma Aldrich, CAT# P8340).
Lysates were run on an SDS-PAGE gel and transferred
to nitrocellulose immunoblot membranes via semi-dry
transfer. Blots were rinsed in ddH2O and allowed to
completely dry before being blocked with PBS-T (PBS,
pH 7.4; Tween-20,0.05%; 5% non-fat dry milk) for
1 hour. After 3 × 5 min PBS-T washes, primary antibodies
(1:1000) suspended in PBS-T complemented with 1%
BSA were then applied to the membrane and incubated
overnight at 4° C. After another 3 × 5 min PBS-T washes,
horseradish peroxidase-conjugated secondary antibodies
suspended in PBS-T were then applied to the membrane.
Then with a final 5 × 5 min PBS-T wash, the membrane
was developed with enhanced chemiluminescence and
imaged using Syngene G:BOX imager. All antibodies used
for the immunoblots were acquired from Cell Signaling
Technologies. STAT3 (CAT#9132), phospho-STAT3
(Y705) (CAT# 9145), Beta-Actin (CAT#3700), NFκB p65
(CAT#8242), phospho-NFκB p65 (CAT#3033), phosphoERK (CAT# 4370), Anti-rabbit IgG-HRP (CAT# 7076).

Animal tumor xenograft model

MCF7 and T47D cells were incubated with 10 ng/
mL of OSM and/or IL-1β for 48 hours at a density of
100,000 cells per well in a 24-well plate. Cells were lysed
with Cell Signaling PathScan® Lysis buffer (Cat# 7018)
using the manufacturer’s instructions. The lysates were
then used on a Dynabeads® Protein A Immunoprecipitation
Kit (Cat# 10006D, Life Technologies) using ERα IP
antibody at 1:50 dilution from Cell Signaling (Cat# D8H8)
in accordance with the kit instructions with the following
modification. In order to reduce co-elution of the antibody,
the antibody was cross-linked using 20 mM dimethyl
pimelimidate dihydrochloride (Cat# 21666, Pierce) in
0.2 M triethanolamine at a pH of 8.2. The antibody-bead
complex was cross-linked for 30 minutes, and the reaction
was stopped by resuspending the beads for 15 minutes in
50 mM pH7.5 Tris. The beads were then used in the rest
of the immunoprecipitation protocol following a 3× PBS0.05% Tween-20 wash.

Immunoprecipitation

Six-week old female athymic nude mice were
purchased from the NCI Animal Production Facility
(Fredrick, MD). The MDATO/OSM cells were grown to
90% confluency and the cells were concentrated to
4.0 × 107 cells/mL in PBS containing 10% RPMI 1640,
and 50 uL of the cell suspension was injected into the 4th
mammary fat pad. When the tumors became palpable, the
animals were given drinking water containing tetracycline
in 2% sucrose water for one week with doses ranging
from 0 mg/mL, 0.1 mg/mL and 1 mg/mL. Animals were
sacrificed and their serum and tumors collected for
analysis. All animal experiments were approved by and
performed in accordance with the animal guidelines of
the Boise Veterans Affairs Medical Center (#JOR0013-1)
Institutional Animal Care and Use Committees.

Immunoblot assay

Statistical analysis

Cells were plated on 24-well plates at 70-80%
confluency and allowed to adhere overnight at 37° C.
Cells were treated with cytokines, OSM (CAT#300-10T)
and/or IL1-Beta (CAT# 200-01B) (Peprotech), and with
inhibitors, the ERK inhibitor PD98059 (CAT# 9900,
Cell Signaling) or the p65 inhibitor caffeic acid phenyl
ester (CAPE) (CAT# 2743, Tocris). Recombinant hOSM
www.oncotarget.com

All the statistical analyses were performed using
GraphPad Prism version 5 software or the RealStatistics™
package for Microsoft Excel. To compare multiple groups,
one- or two-way ANOVA was performed using Tukey’s
post-test where appropriate. Comparisons between two
groups were assessed by unpaired two-tailed student’s
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t-test. Correlations were assessed using the Spearman
nonparametric correlation analysis. Survival data was
assessed using the Log-rank test. Statistical significance
was assigned to experimental p values that were less than
0.05. Error bars represent the standard error of the mean
unless otherwise specified, and all experiments were
performed at least three times.
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